Scenesse is a medicine that can give sufferers of Erythropoietic Protoporphyria (EPP) a new lease on life. The FDA approval of Scenesse for EPP in October 2019 was a watershed moment for US patients with this devastating disease. It has been a long time coming and is now ready for use. Because it was just approved by the FDA, it will require a lot of flips and twists to get it to the patients who need it. The path starts by establishing your account with us via Klara, by going to this link. You will then contact us to set up your EPP consultation. Please understand that Scenesse is neither approved nor available for patients with Vitiligo, Polymorphous Light Eruption and other photosensitive diseases. Yet. Stay tuned here, as we constantly update our Blog, Facebook and Instagram accounts as we get new information.
Scenesse now available for Erythropoietic Protoporphyria (EPP)
Love this Post? Spread the World